<< Cancer Prevention Coalition's statement on new nominated NCI Director | Contaminated insects: A potential threat for meat-eating plants >>

AMAG Pharmaceuticals and Takeda Pharmaceuticals sign collaboration agreement

Published on April 3, 2010 at 4:03 AM · No Comments

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) will host a conference call and webcast today at 8:00 am ET to discuss today's announcement that AMAG Pharmaceuticals, Inc. and Takeda Pharmaceuticals Company have entered into a strategic collaboration agreement related to Feraheme® (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications in select ex-US territories.

Source: AMAG Pharmaceuticals, Inc.

486f50ae-0a8a-4d38-8863-ab9de61c66b4|0|.0

Posted in: Pharmaceutical News

Tags: Anemia, Cancer, Iron Deficiency, Kidney Disease

Drugs can save African infants' livesResearchers at the University of Sydney have found the combined intake of iron-folic acid supplement...
Adding rosemary extracts in ground beef can reduce cancer-causing agentsThe addition of rosemary extract to ground beef actually reduces cancer-causing agents that can form...
Potential gene target for treatment of common hearing, vertigo and balance problemsA UCLA study shows for the first time how microscopic crystals form sound and gravity sensors inside...
UIC receives $20 million NCI grant to research blood disordersA $19.6 million National Cancer Institute grant has been awarded to the University of Illinois at Ch...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.